21829-25-4 HYIMSNHJOBLJNT-UHFFFAOYSA-N HYIMSNHJOBLJNT-UHFFFAOYSA-N Nifedipine 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-, dimethyl ester 1,4-Dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylic acid dimethyl ester 2,6-Dimethyl-3,5-dicarbomethoxy-4-(2-nitrophenyl)-1,4-dihydropyridine 2,6-Dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid dimethyl ester 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-, 3,5-dimethyl ester 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(o-nitrophenyl)-, dimethyl ester 4-(2'-Nitrophenyl)-2,6-dimethyl-3,5-dicarbomethoxy-1,4-dihydropyridine 4-(2-Nitrophenyl)-2,6-dimethyl-3,5-dicarbomethoxy-1,4-dihydropyridine Adalat CC Adalat CR Adalat Crono Adalat FT Adalat GITS Adalat GITS 30 Adalat LA Adalat LP Adalat Oros Adalat PA Adalat retard Adalate Adapine Adapress Aldipin Alfadat Alonix S Alpha-Nifedipine Retard Angipec Apo-Nifed Aprical Calcibloc Calcigard Calciguard Calcilat Cardifen Cardilat Cardionorm Chronadalate Chronadalate LP Citilat Coracten Cordafen Cordaflex Cordalat Cordicant Cordilan Cordipin Corinfar Corotrend Corynphar Dignokonstant Dilafed Dimethyl 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylate Dimethyl 4-(o-Nitrophenyl)-2,6-dimethyl-1,4-dihydro-3,5-pyridinedicarboxylate Dipinkor Duranifin Ecodipi Ecodipin Ecodipin E Fedcor Retard Fedipin Fenamon Fenamon SR Fenihidine Hadipine Hexadilat Introcar Kordafen Macorel Megalat Myogard Nedipin Nicardia Nicardia retard Nifangin Nifdemin Nifebene Nifecard Nifecor Nifedate Nifedepat Nifedicor NIfedilat Nifedin Nifedine Nifedipin Nifedipine retard nifedipino Nifedipres Nifedirex LP Nifelan Nifelantern Nifelat Nifelat Q Nifelate Nifensar XL Nificard Nifidine Nifipen Niphedipine Normadil Novo Nifedin Nyefax Retard Osmo-Adalat Pidilat Procardia Procardia XL Sepamit Sepamit R Slofedipine XL Tensopin Tibricol UV-ENP 349PINA Vasdalat Vasdalat Retard Vasofed Zenusin DTXSID2025715 88150-42-9 HTIQEAQVCYTUBX-UHFFFAOYNA-N HTIQEAQVCYTUBX-UHFFFAOYSA-N Amlodipine 3,5-Pyridinedicarboxylic acid, 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-, 3-ethyl 5-methyl ester (R,S)-Amlodipine 2-[(2-Aminoethoxy)methyl]-4-(2-chlorophenyl)-3-(ethoxycarbonyl)-5-(methoxycarbonyl)-6-methyl-1,4-dihydropyridine 3-Ethyl 5-methyl 2(2-aminoethoxymethyl)-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate Amlopres Intervask Racemic Amlodipine DTXSID7022596 72509-76-3 RZTAMFZIAATZDJ-UHFFFAOYNA-N RZTAMFZIAATZDJ-UHFFFAOYSA-N Felodipine 3,5-Pyridinedicarboxylic acid, 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-, ethyl methyl ester DTXSID4023042 63675-72-9 VKQFCGNPDRICFG-UHFFFAOYNA-N VKQFCGNPDRICFG-UHFFFAOYSA-N Nisoldipine 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-, methyl 2-methylpropyl ester (.+-.)-BAY k 5552 (.+-.)-Nisoldipine 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-, 3-methyl 5-(2-methylpropyl) ester Baymycard Nisocor Nisoldipin nisoldipino Norvasc Zadipina DTXSID0023371 66085-59-4 UIAGMCDKSXEBJQ-UHFFFAOYNA-N UIAGMCDKSXEBJQ-UHFFFAOYSA-N Nimodipine 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-methoxyethyl 1-methylethyl ester (.+-.)-Nimodipine 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 3-(2-methoxyethyl) 5-(1-methylethyl) ester Nimodipin Nimodipine AP nimodipino Nimotop Periplum DTXSID5023370 39562-70-4 PVHUJELLJLJGLN-UHFFFAOYNA-N PVHUJELLJLJGLN-UHFFFAOYSA-N Nitrendipine 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, ethyl methyl ester (.+-.)-BAY E 5009 (.+-.)-Nitrendipine 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 3-ethyl 5-methyl ester Bayotensin Baypress Bylotensin Nitrendipin nitrendipino Nitrepin DTXSID0023373 42399-41-7 HSUGRBWQSSZJOP-RTWAWAEBSA-N HSUGRBWQSSZJOP-RTWAWAEBSA-N (+)-Diltiazem 1,5-Benzothiazepin-4(5H)-one, 3-(acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-, (2S,3S)- (+)-cis-Diltiazem (+)-Diltiazem 1,5-Benzothiazepin-4(5H)-one, 3-(acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-, (2S-cis)- Adizem XL Cartia XT d-cis-Diltiazem d-Diltiazem Dilzem retard DTXSID9022940 52-53-9 SGTNSNPWRIOYBX-UHFFFAOYNA-N SGTNSNPWRIOYBX-UHFFFAOYSA-N (+/-)-Verapamil Benzeneacetonitrile, α-[3-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]propyl]-3,4-dimethoxy-α-(1-methylethyl)- (.+-.)-Verapamil 5-[(3,4-Dimethoxyphenethyl)methylamino]-2-(3,4-dimethoxy phenyl)-2-isopropylvaleronitrile dl-Verapamil Iproveratril NSC 272306NA R,S-Verapamil Valeronitrile, 5-[(3,4-dimethoxyphenethyl)methylamino]-2-(3,4-dimethoxyphenyl)-2-isopropyl- verapamilo α-[3-[[2-(3,4-Dimethoxyphenyl)ethyl]methylamino]propyl]-3,4-dimethoxy-α-(1-methylethyl)benzeneacetonitrile DTXSID9041152 Calcium channel blockers 2018-06-21T04:57:36 2018-06-21T04:57:36 Nifedipine 2018-11-02T07:40:44 2018-11-02T07:40:44 Amlodipine 2018-11-02T07:41:21 2018-11-02T07:41:21 Felodipine 2018-11-02T07:41:59 2018-11-02T07:41:59 Nisoldipine 2018-11-02T07:42:24 2018-11-02T07:42:24 Nimodipine 2018-11-02T07:42:56 2018-11-02T07:42:56 Nitrendipine 2018-11-02T07:43:23 2018-11-02T07:43:23 Diltiazem 2018-11-02T07:43:44 2018-11-02T07:43:44 Verapamil 2016-11-29T18:42:27 2016-11-29T18:42:27 WikiUser_28 Vertebrates Blockade, L-Type Calcium Channels Molecular UBERON:0000948 UBERON heart CL:0000746 CL cardiac muscle cell AOPWiki 2018-06-19T13:37:57 2018-11-01T12:25:14 Decrease, Calcium currents Cellular AOPWiki 2018-06-19T13:43:00 2018-06-19T14:19:36 Decrease, Calcium binding to Troponin C Cellular AOPWiki 2018-06-19T13:58:26 2018-06-19T13:58:26 Decrease, Cardiac contractility Organ AOPWiki 2018-06-19T14:01:46 2018-06-19T14:02:04 Decrease, Cardiac ejection fraction Organ AOPWiki 2018-06-19T14:03:00 2018-06-19T14:03:00 Heart failure Organ AOPWiki 2018-06-19T14:04:03 2018-06-19T14:04:03 Disruption, Intracellular calcium mobilization Cellular AOPWiki 2018-06-21T04:46:05 2018-06-21T04:46:05 Disruption, Sarcomere assembly Cellular AOPWiki 2018-06-21T04:46:43 2018-06-21T04:46:43 #<Reference::ActiveRecord_Associations_CollectionProxy:0x00007b430ba419c8> AOPWiki 2018-06-19T13:54:46 2018-06-19T13:54:46 #<Reference::ActiveRecord_Associations_CollectionProxy:0x00007b430ba83990> AOPWiki 2018-06-19T14:04:33 2018-06-19T14:04:33 #<Reference::ActiveRecord_Associations_CollectionProxy:0x00007b42e9742848> AOPWiki 2018-06-19T14:04:53 2018-06-19T14:04:53 #<Reference::ActiveRecord_Associations_CollectionProxy:0x00007b42e97686d8> AOPWiki 2018-06-19T14:05:14 2018-06-19T14:05:14 #<Reference::ActiveRecord_Associations_CollectionProxy:0x00007b42e979b2e0> AOPWiki 2018-06-19T14:08:03 2018-06-19T14:08:03 #<Reference::ActiveRecord_Associations_CollectionProxy:0x00007b42e97bda70> AOPWiki 2018-06-21T04:48:00 2018-06-21T04:48:00 #<Reference::ActiveRecord_Associations_CollectionProxy:0x00007b42e97d8988> AOPWiki 2018-06-21T04:48:28 2018-06-21T04:48:28 #<Reference::ActiveRecord_Associations_CollectionProxy:0x00007b42e97ff1a0> AOPWiki 2018-06-21T04:48:54 2018-06-21T04:48:54 L-type calcium channel blockade leading to heart failure via contractility decrease Arthur Author <p><span style="font-size:14px">Luigi Margiotta-Casaluci, Brunel University London, UK (luigi.margiotta-casaluci@brunel.ac.uk)</span></p> All rights reserved Under Development 1.45 2.0 <p><span style="font-family:arial,helvetica,sans-serif"><span style="font-size:14px">Calcium ions play a vital role in cellular and organism physiology. These ions are a central component of a complex system of intracellular messenger that mediates a wide range of biological processes. In the heart, calcium dynamics and signaling are essential for cardiac muscle contraction, thus the perturbation of these processes may impair organ function and health. Different types of calcium channels contribute to the timely regulation of calcium currents at the cellular level. Among them, the L-type calcium channels (LTCCs) are responsible for the excitation-contraction coupling of skeletal, smooth, and cardiac muscle. The pharmacological modulation of this target is an important tool for the treatment of cardiac pathologies, and several drugs that block LTCCs have been developed in the last few decades. However, pharmaceuticals (or any other chemical) that unintentionally block this channel in cardiac cells may lead to adverse cardiovascular effects.</span></span></p> <p><span style="font-family:arial,helvetica,sans-serif"><span style="font-size:14px">This AOP describes the mechanistic linkage between LTCCs blockade and heart failure mediated by the decrease in cardiac contractility and reduction of ejection fraction. This AOP should be considered part of a network, together with AOP 262. The AOP development was based on over 1,100 in vitro, ex vivo and in vivo data points extracted from approximately 150 publications that investigated a) the effects of calcium channel blockers on different components of the cardiovascular system, and b) the effects of genetic manipulations of the drug target. For each Key Event (KE), a quantitative analysis was performed to determine effect direction and degree of responsiveness. A database-specific confidence index was assigned to each KE according to the degree of reproducibility of the effect. Many KEs of this AOP can be experimentally quantified using different specific endpoints. Therefore, the responsiveness analysis of each endpoint was performed to quantify the sensitivity of each measurement to the blockade of LTCCs. This knowledge has both biological and methodological significance. In the latter case, it can effectively inform the development of suitable testing strategies aimed at maximizing the probability to detect changes in a given KE. Several <em>in silico </em>methods are currently available to determine the quantitative relationship between various KEs in the two proposed AOPs in humans. Future development efforts will be aimed at combining those different methods to develop a fully quantitative AOP network. This AOP is intended to support the interpretation of the cardiovascular risk associated with drug-induced blockade of LTCCs.</span></span></p> <p><span style="font-size:14px"><span style="font-family:arial,helvetica,sans-serif">Cardiovascular safety liabilities remain a major cause of drug attrition during preclinical and clinical development. Drug-induced cardiovascular toxicity was identified as an area of potential interest for AOP development by a network of experts convened by the UK National Centre for the Replacement, Refinement, and Reduction of Animals in Research (NC3Rs) and the European Union Reference Laboratory for alternatives to animal testing (EURL-ECVAM) in 2015. The blockade of L-type calcium channels (LTCCs) was proposed as one of the priority molecular initiating events (MIE) that may benefit from the AOP vision.</span></span></p> <p><span style="font-size:14px"><span style="font-family:arial,helvetica,sans-serif">From a toxicological perspective, the key importance of ion currents for drug safety came to light with the discovery that hERG potassium channel inhibition is the most common mechanism of drug-induced long QT syndrome and torsades de pointes arrhythmia [PMID:16322774]. However, a growing body of research has demonstrated that drugs can affect more cardiac currents than previously expected (e.g. calcium current). Thus, the integrated assessment of drug inhibitory activity for multiple ion currents may provide a more accurate prediction of the toxicological risk [PMID:16322774]. Considering the newly recognized complexity of the phenomenon, several authors called for dedicated inter-disciplinary efforts aimed at improving our understanding of the mechanistic basis of cardiovascular liabilities, beyond hERG current blockade [PMID: 21306581]. This AOP is intended to support those efforts by providing a detailed map of the multi-scale effects mediated by LTCCs-blockade.</span></span></p> adjacent High High adjacent High High adjacent High High adjacent High High adjacent High High adjacent Moderate High adjacent Low Moderate adjacent Low High High Male High Female High All life stages High High High High High High High High High High AOPWiki 2018-05-10T08:37:07 2023-09-25T16:26:58